T he prevalence of leg ulceration remains relatively constant and continues to affect 0.14-2% of the population, depending on the methodology used.
1-4 Approximately 70% of leg ulcers are of venous aetiology. Chronic venous leg ulcers are associated with protracted treatment, a high recurrence rate, high associated health-service costs and a reduced quality of life. 5, 6 Approximately 50% of venous ulcers heal after 12 weeks of compression therapy. 7 The two most positive predictors of healing within 24 weeks are a wound size of less than 5cm 2 and a duration of less than six months at the initial presentation. 8.9 A recent systematic review of 42 randomised controlled trials (RCTs) involving 3001 patients evaluated the effect of dressings on healing outcomes for venous leg ulcers. 10 This concluded that there is insuffi cient evidence that any one type of dressing heals ulcers more quickly than others. It highlighted the poor methodological quality and small sample sizes of many of the studies. A further limitation of many studies on topical agents for venous leg ulcers is the lack of information on the condition of the wound bed at the start of treatment and its potential infl uence on healing outcomes.
Slough provides a nidus for infection, prolongs infl ammation, increases metabolic load and impairs visualisation of the wound bed. [11] [12] [13] As venous ulcers can harbour up to four different pathogens, 14-16 the presence of slough in the wound bed increases the potential for infection. The ongoing presence of virulent microorganisms prolongs the infl ammatory response, which eventually contributes to host injury. There is persistent production of infl ammatory mediators and a steady migration of neutrophils, which release proteolytic enzymes and oxygen-free radicals. 17 Localised thrombosis and the release of vasoconstricting metabolites can lead to tissue hypoxia, promoting further bacterial proliferation and tissue destruction. 17 The destructive action of bacteria on wound tissue can therefore increase the production of slough. As such, it could be argued that wounds in which slough is the predominant tissue will heal more slowly than clean granulating wounds.
Honey is not a generic agent and in vitro studies
• Objective: To determine the qualitative bacteriological changes that occurred during a four-week treatment period with either manuka honey or a hydrogel dressing. This was the secondary outcome of a randomised controlled trial (RCT) that compared the effi cacy of the two treatments in desloughing venous leg ulcers.
• Method: This was a prospective open label multicentre RCT with blinded microbiological outcome analysis. Randomisation was conducted via remote telephone. To be included, the wound bed needed to comprise at least 50% slough. Wound swabs were taken at the start of treatment and after four weeks.
• Results: In all, 108 patients (35 males, 73 females) aged 24-89 years (mean 68) enrolled into the study. Both groups were comparable at baseline. Eighteen patients (17%) were withdrawn due to a wound infection: six in the honey group and 12 in the hydrogel group. Staphylococcus aureus was the most common isolate, being identifi ed in 41 wounds (38%). At baseline, meticillin-resistant Staphylococcus aureus was identifi ed in 16 wounds (10 honey versus six hydrogel). After four weeks 70% (n=7) of the manukahoney treated wounds versus 16% (n=1) of the hydrogel treated wounds had MRSA eradicated.
Pseudomonas aeruginosa was reported in 14% (n=16) of all wounds at baseline. After four weeks 33% (n=2) treated with honey and 50% (n=5) treated with hydrogel had this eliminated. The number of wounds (n=11 at baseline; n=15 at week 4) with ≥3 bacteria species remained constant over the four weeks.
• Conclusion: Manuka honey was effective in eradicating MRSA from 70% of chronic venous ulcers. The potential to prevent infection is increased when wounds are desloughed and MRSA is eliminated. This can be benefi cial to prevent cross-infection.
• Declaration of interest: None. have demonstrated that manuka honey has antibacterial properties against a wide range of wound-colonising organisms including Staphylococcus aureus, Pseudomonas aeruginosa and streptococcus, 18, 19 the fi rst being one of the most common pathogens colonising venous ulcers. 14, 16 Many reports have verifi ed the antimicrobial properties of honey, but its mechanisms of action have only been partially studied. 18, 20, 21 The antimicrobial activity of different honeys can vary by up to 100-fold. 22, 23 Studies have demonstrated that manuka honey has high antibacterial activity associated with a non-peroxide, unidentifi ed, phytochemical component. 18, [22] [23] [24] [25] In vitro studies on manuka honey, where its antibacterial potency was near the median level, showed the minimum inhibitory concentration (MIC) was 2-3% for Staphylococcus aureus, 3.3-4% for coagulase-negative staphylococci, 5.5-9% for Pseudomonas aeruginosa, 2.7-3% for MRSA and 3.8-5% for vancomycin-resistant enterococcus. 18, 19, 26, 27 Condon 28 argued that the antimicrobial effect of honey lies in its physical properties rather than its chemical composition. Honey is hyperosmolar and so restricts the availability of environmental water to bacteria and other organisms. 28 Additionally, because bacterial cells are largely impermeable to sucrose and similar sugars, honey also osmotically withdraws water from bacteria. 28 This simple process could contribute to the management of the bacterial burden in the wound.
The benefi ts of this antibacterial activity remain speculative, and as yet no published clinical studies have determined the effect of honey on wound bacteria. Although many reports and trials have documented the bacterial fl ora present, they have not correlated healing times with the reduction in bacterial load. 29 The high osmolarity of honey stimulates the outfl ow of fl uid from the deeper wound compartments to the surface, thus aiding wound cleansing and contributing to wound debridement. However, our knowledge of the effi cacy of honey as a debriding agent is based on case studies 20, 30, 31 as this has not yet been tested in a RCT.
We conducted a RCT to compare the effi cacy of manuka honey (WoundCare 18+, Comvita, New Zealand) with hydrogel therapy (Intrasite Gel, Smith & Nephew, UK) in desloughing venous leg ulcers. 32 The primary outcome measures were to determine the ability of manuka honey to deslough venous leg ulcers over four weeks and measure its effects on healing rates after 12 weeks, when compared with the standard agent. These will be published elsewhere.
A secondary outcome measure was to monitor changes in the qualitative bacteriological analysis of culture swabs taken from sloughy venous ulcers over the four-week treatment period. This paper focuses on the secondary outcome.
Method
This prospective open-label multicentre RCT was conduced between February 2003 and January 2006.
Patients presenting with venous leg ulcers where >50% of the wound area was covered in slough and who were able to provide written informed consent were considered for inclusion.
Inclusion and exclusion criteria were based on an ankle brachial pressure index (ABPI) of >0.8 where no other causative aetiology was present and the ulcer appeared to be venous on clinical examination. Patients were excluded if the wound was greater than 100cm 2 , they had a current wound infection or an infection elsewhere on the body requiring antibiotics, were taking steroids or they were allergic to any type of honey or hydrogels.
Approval was gained from the ethics committees representing study sites.
A priori calculation determined that 156 patients were required to show a 20% difference between the treatments for the primary outcome at a two-sided signifi cance level.
Patients were enrolled from 10 sites which included vascular and specialist wound clinics and community leg ulcer clinics. Baseline data collection included ulcer size and duration, ulcer location and history of recurrence, history of deep venous thrombosis (DVT), hypertension, trauma or surgery to the affected limb, diabetes, immunosuppression therapy and current medications. Randomisation was via remote telephone.
Compression therapy was continued in all cases. Patients were treated with the allocated treatment for four weeks and then followed up at week 12 to determine if their ulcer had healed. Treatment was applied weekly as follows: manuka honey 5g/20cm 2 and hydrogel 3g/20cm 2 . The dose differential was accounted for by the viscosity of the agents.
At the fi rst assessment visit (before randomisation), two culture swabs were taken after the wound was cleansed with warm tap water; two swabs were taken to safeguard against loss or damage to the swab or the result. A cotton-tipped swab was rotated 360° in the wound bed. To emulate routine clinical practice, the swabs were placed in transport media and transported immediately to the laboratory for routine qualitative culture. Repeat swabs were taken, using the same procedure, after one week and four weeks of treatment. The laboratory was blinded to treatment allocation.
Wound size was recorded weekly using digital planimetry (Visitrak, Smith & Nephew). Pain was assessed weekly using a validated fi ve-point visual analogue scale, where 0 = no pain and 5 = severe or worst ever pain. 33 The bacteria are presented in the results section as reported on the laboratory report forms, to show similarity with routine clinical practice. 
Statistical analysis
Data were entered into SPSS version 14. The primary analysis was conducted on an intention-to-treat basis. Non-parametric two-sample Mann-Whitney U test was used to investigate the signifi cance of the differences observed between the two interventions in relation to pain. Statistical signifi cance was considered when p values were 0.05 or less. The logrank test for equality of survival functions was used to determine if there was a signifi cant difference between the two groups in the number of patients who were withdrawn from the study because of a wound infection. The outcome variable was the week of withdrawal. The chi-square test was used to compare categorical demographic and baseline variable data. Baseline differences between groups were examined using the independent samples t-test for independent groups.
Results
A total of 108 patients, allocated to two groups of 54, were enrolled over 34 months. Baseline patient characteristics were comparable in the two groups (Table 1) .
During the four-week treatment period, 18 patients (17%) were withdrawn due to a wound infection (six in the honey group versus 12 in the hydrogel group). Infection was diagnosed on clinical presentation and included factors such as increased pain, increased wound size, increased exudate and surrounding cellulitis. This difference was clinically but not statistically different (χ 2 =3.11, p=0.077). No differences or trends were noted, based on the week of withdrawal or bacterial species reported.
At baseline, the two groups were comparable in terms of the number of bacterial species (χ 2 5.152, p=0.27) ( Table 2 ). This comparability was maintained throughout the treatment period ( Table 2) . None of the ulcers or their surrounding skin showed signs of infl ammation at baseline. Table 3 reports on the bacterial species identifi ed at baseline and at the end of week 4, based on treatment allocation and their frequency of occurrence. Interestingly, wounds with a longer duration had more bacterial species than those with a shorter duration (Table 4) .
Staphyloccocus was the most common wound isolate at baseline, being found in 38% (n=41) of all wounds. At baseline, meticillin-resistant Staphylococcus aureus (MRSA) was isolated in 10 ulcers in the honey group and six in the hydrogel group. After four weeks a 'case-by-case' review showed that this reduced to 3/10 ulcers in the honey group compared with 5/6 in the hydrogel group. The mean age of patients with MRSA was 76 years (range 52-86, median 78), which is higher than that of the entire study population (mean 68 years).
At baseline Pseudomonas aeruginosa was isolated in six ulcers in the honey group and 10 ulcers in the hydrogel group. Of those individual wounds with Pseudomonas aeruginosa at baseline, only 33% (n=2) treated with honey and 50% (n=5) treated with hydrogel had this eliminated by week 4. The mean wound area of all ulcers colonised with Pseudomonas aeruginosa at baseline was 15.9cm 2 , which was 50% greater than that of the overall study population (10.1cm
2 ). At baseline, wounds colonised with Pseudomonas aeruginosa had a mean surface area of slough of 83%, which reduced to 60% after four weeks. This was lower than the mean reduction in the percentage of slough (82-36%) for the entire study population.
Mean baseline pain scores were 1. * Data were missing due to withdrawals and healing as the trial progressed the groups in the mean percentage reduction in wound pain at week 1: honey reduced by 52% versus 34% for hydrogel; this was statistically significant in favour of honey (p<0.05). No further statistically signifi cant differences were found between the groups at weekly intervals or from baseline to the end of each week. An increase in the intensity or nature of pain may indicate that a chronic wound has become infected. 34 Regarding the 18 infected ulcers, during the treatment period pain increased in seven (39%), remained unchanged in six (33%) and decreased in fi ve (28%). In addition, 11 of these 18 ulcers (61%) increased in size, two remained unchanged (11%) and fi ve reduced in size (28%).
Discussion
This is the fi rst randomised in vivo study to compare the effi cacy of manuka honey with a comparator on the bacterial burden of sloughy venous ulcers. The hydrogel dressing was used as the comparator because it is a standard desloughing agent; IntraSite Gel was chosen because it was the most commonly used hydrogel in the study sites.
Wound infection was the most common reason for withdrawal from the study (n=18). This is an important clinical fi nding as the literature has not identifi ed the rate of infection that can be expected in patients with chronic venous leg ulcers. However, chronic venous leg ulcers are persistently colonised subclinically.
14, 35 We did not include subclinical colonisation as an exclusion criteria, and it could be that the infection rate refl ected the severity of wound colonisation at baseline. As slough was the predominant tissue in the wound bed at baseline, this rate of infection was not unexpected.
While there was no statistically signifi cant difference in the infection rate between the two groups, more cases were reported in the hydrogel group (n=12) than in the honey group (n=6). This may be 
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Alpha-haemolytic streptococcus 1 attributed to differences in the antimicrobial properties of the two treatments. We therefore hypothesise that topical desloughing agents used on chronic wounds, such as venous ulcers, should have antimicrobial properties, although further research is needed to support this. The polymicrobial nature of the ulcers reported in the present study was similar to that reported elsewhere.
14,16, 35 In our study, 13 ulcers (12%) had 'no bacterial growth' at baseline, which, given the condition of the wound bed, is a high number as over 50% of the wound bed was covered in slough, which harbours bacteria.
Staphylococcus aureus was the most common wound isolate. However, its prevalence was much lower than the 54-88% reported in studies involving patients with lower limb ulceration. 15, 16, 35 This may be due to differences in sampling techniques and methods of analysis. 15, 35, 36 Sixteen patients had MRSA at baseline. This is an important fi nding as it indicates the prevalence of this bacterium in the venous leg ulcer population. However, this may be an underestimation as patients with chronic wounds take 10 times more courses of antibiotics than the general population, increasing the risk of resistance. 15 The mean age of patients with MRSA was 76 years, which is higher than the overall study population mean, supporting the fi nding that MRSA is more prevalent in older people. 37 Manuka honey effectively eradicated MRSA in 70% of cases. In vitro studies have confi rmed the effi cacy of manuka honey against Staphylococcus aureus, including MRSA. 18, 24, 38 Before this study, evidence on the effi cacy of honey (varying types) in eliminating MRSA from chronic wounds was limited to in vitro studies and a few case studies. 19, [39] [40] [41] MRSA has been removed from colonised leg ulcers, 30, 40 chronic wounds of patients undergoing maxillofacial surgery 42 and wounds in paediatric oncology patients. 43 Blaser et al. 44 described how Medihoney (which contains manuka) eradicated MRSA in the chronic wounds of different aetiologies in seven patients. The infection had persisted for up to fi ve years in some cases, despite the selected use of topical antiseptics, topical antibiotics and systemic vancomycin. 44 Further research is needed to test our fi ndings in a larger cohort of MRSA-positive wounds. This could have implications for wound management, particularly in the acute hospital setting where there is a greater risk of cross-contamination.
Pseudomonas aeruginosa, was present in 14% of all wounds at baseline, and is associated with non-healing in up to 60% of wounds. 35 35, 45 It is interesting that the hydrogel performed better in this aspect of microbiological control as it does not have antibacterial properties and both agents promote a moist environment. The presence of Pseudomonas aeruginosa was also associated with larger ulcers and less effi cacious removal of slough.
In an in vitro analysis, Cooper and Molan proposed that manuka honey may inhibit growth of Pseudomonas aeruginosa, even if the honey was diluted more than 10-fold by wound exudate. 26 However, this was not supported in two case studies 31, 46 or the present study. Furthermore, in an in vitro study Willix et al. 24 noted that, of all organisms tested, Pseudomonas aeruginosa was the least sensitive to manuka honey.
Limitations
The main study limitation was the failure to recruit the predetermined number of participants. However, the sample size of 108 still represents the largest study on sloughy venous ulcers and the effi cacy of manuka honey in the management of bacterial burden. Quantitative bacteriological analysis may have provided more in-depth analysis but, as bacterial changes were not the primary outcome, this method was not justifi ed. The small numbers in each group mean that statistical interpretation of fi ndings was limited. However, we hope that the fi ndings may add to the body of knowledge on the use of manuka honey in chronic wounds. The fi ndings are only truly applicable to sloughy venous ulcers and to manuka honey.
Conclusion
Sloughy venous ulcers harbour a wide range of pathogens. The effi cacy of honey in eliminating MRSA in such wounds is a positive fi nding that may have implications for wound management and infection control. The use of manuka honey was associated with a signifi cant reduction in wound pain after one week. Future clinical studies are warranted to determine optimal dosage regimens for antimicrobial effi cacy. ■ neuropad® is an adhesive dressing applied to the plantar surface of the foot to assess the function of the sweat glands by measuring the moisture status of the foot, indicated by colour change. An abnormal sweat gland response is closely correlated with the onset of peripheral autonomic neuropathy in the feet.
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